RxDoctor Payments Data

Andrew Weinberg, DO

Cardiovascular Disease · Fayetteville, NYNPI 1750572657

Payments from drug & device makers

$23,568in general payments, 2019–2025

Across 181 payments — averaging $130.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Biotronik Inc.$2K
  • Abbott$1K
  • Johnson & Johnson$199
  • Boston Scientific$198
  • Abiomed$185
  • plus $582 from 14 others

What the payments were for

  • Speaking & faculty fees$11,68250%
  • Travel & lodging$6,87029%
  • Food & beverage$4,95821%
  • Education$120%
  • Other$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,568 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$204,261
Medicare patients
739
Services billed
1,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$473,204
XareltoRivaroxaban155$170,748
EntrestoSacubitril/Valsartan129$158,270
JardianceEmpagliflozin45$48,264
BrilintaTicagrelor20$23,821
Repatha SureclickEvolocumab28$20,704
Metoprolol Succinate554$7,375
VascepaIcosapent Ethyl13$6,743
Atorvastatin Calcium544$5,311
Flecainide Acetate100$2,674
Diltiazem 24hr Er (Cd)Diltiazem Hcl86$2,671
Rosuvastatin Calcium190$2,635
Nebivolol Hcl46$2,376
ClopidogrelClopidogrel Bisulfate230$2,022
Amlodipine Besylate328$1,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$473,204376 claims
Johnson & JohnsonXarelto$199$170,748155 claims
NovartisEntresto$173$158,270129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Fayetteville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →